Breast Cancer
Data from Myriad Genetics offered early validation evidence for an expanded version of its commercial test, as well as a look into clinical impact via claims data.
Natera, MyOme Partner to Launch Cross-Ancestry, Integrated Breast Cancer Polygenic Risk Score
The cross-ancestry iPRS will be available to patients who receive a negative test result with Natera's Empower hereditary cancer test.
HER2 Biomarker Evolving as Enhertu Shows Activity in Breast Cancers With Ultralow Expression
Premium
The new HER2-low category is exposing the limitations of IHC testing, challenging pathologists, and has oncologists revisiting patients' old test results.
Coined SEQUOIA, the AI model was able to predict expression profiles for thousands of genes in cancer samples using whole-slide images.
Reveal Genomics Studying HER2DX Test Impact on Breast Cancer Treatment Decisions
The trial done in collaboration with the Istituto Europeo di Oncologia will assess how the test influences oncologists' treatment plans for early-stage breast cancer patients.